Document:

prop_ex1017.htm

EXHIBIT 10.17

 

SUBSCRIPTION AGREEMENT F

OR THE PURCHASE OF SHARES OF COMMON STOCK

Propanc Health Group Corporation, a Delaware corporation (the “Company”) is offering (this “Offering”) for sale to ____________  (the “Investor”) to an aggregate of  ___________ shares of its common stock, par value $0.001 per share (the “Common Stock”) at $1.50 per share of common stock.  This Offering is made by the Company, acting without a placement agent, pursuant to the Registration Statement File No.: 333-175092 declared effective by the U.S. Securities and Exchange Commission (the “Commission”) on ______________ (the “Registration Statement”) and this subscription agreement (this “Agreement”).

WHEREAS, the Company filed the Registration Statement to sell a minimum amount of 500,000 and a maximum of up to 5,000,000 shares of our common stock on a best efforts basis and the Registration Statement was declared effective  by the Commission; and

WHEREAS, the Company is offering for sale to the Investor an aggregate of _____________ shares of its Common Stock on the terms agreed to herein.

NOW, THEREFORE, IT IS HEREBY AGREED:

Purchase of Shares

(a)           The undersigned Investor agrees to purchase at the Closing (as defined herein) and the Company agrees to sell and issue at the Closing _____________ Shares of Common Stock, at a price of $1.50 per share (the “Shares”), for a total subscription amount of $____________ (the “Subscription Amount”).

(b)           The Investor and the Company agree that the Subscription Amount shall be paid by or on behalf of the Investor by bank draft or check payable to Propanc Health Group Corporation and is subject to acceptance  by the Company (the “Closing”).

Subscription Procedures

(a)           To subscribe, the Investor must:

(i)           complete and sign this Agreement;

	
  

	
(ii)

	
complete and sign the accompanying Confidential Prospective Purchaser Questionnaire (this Agreement and the Registration Statement are collectively referred to herein as the “Offering Documents”);

	
  

	
(iii)

	
return the completed and signed Offering Documents and the check or bank draft payable to Propanc Health Group Corporation on behalf of the Investor to the following address:

 

 

  

1

  

 

Propanc Health Group Corporation

576 Swan Street

Richmond, VIC, 3121, Australia

Prospective Investors should retain their own professional advisors to review and evaluate the economic, tax, and other consequences of an investment in the Company.

THE COMMISSION HAS NOT PASSED UPON THE ACCURACY OR ADEQUACY OF THE OFFERING DOCUMENTS. NO STATE SECURITIES LAW ADMINISTRATOR HAS PASSED ON OR ENDORSED THE MERITS OF THIS OFFERING OR THE ACCURACY OR THE ADEQUACY OF THE OFFERING DOCUMENTS. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.

THE SECURITIES OFFERED HEREBY SHOULD BE CONSIDERED ONLY BY PERSONS WHO CAN AFFORD TO SUSTAIN A LOSS OF THEIR ENTIRE INVESTMENT.

NASAA UNIFORM LEGEND

IN MAKING AN INVESTMENT DECISION INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE COMPANY AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. THESE SECURITIES HAVE NOT BEEN RECOMMENDED BY ANY FEDERAL OR STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY. FURTHERMORE, THE FOREGOING AUTHORITIES HAVE NOT CONFIRMED THE ACCURACY OR DETERMINED THE ADEQUACY OF THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

 

 

  

2

  

 

PROPANC HEALTH GROUP CORPORATION

SUBSCRIPTION AGREEMENT FOR THE PURCHASE OF

SHARES OF COMMON STOCK

1.           Unless terminated earlier by the Company, in its sole discretion, this Offering is scheduled to terminate on or about _________________, 5:00 p.m., New York time, unless extended for an additional 90 days (the “Offering Period”).

2.           For additional information regarding the Company, the Investors are encouraged to review the Company’s Registration Statement (collectively referred to herein as the “Exchange Filings”).

3.           The Company hereby makes the following representations, warranties and covenants to the Investors:

a.           The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder.

b.           The execution and delivery of this Agreement by the Company and the consummation by it of the transactions contemplated hereunder have been duly authorized by all necessary corporate action on the part of the Company.

c.           This Agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as may be limited by any bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or other similar laws affecting the enforcement of creditors’ and contracting parties’ rights generally or by general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law).

4.           Each Investor hereby makes the following representations, warranties and covenants to the Company:

a.      Each Investor is aware that the purchase of the Shares is a speculative investment involving a high degree of risk and that there is no guarantee that the Investor will realize any gain from this investment, and that the Investor could lose the total amount of the Investor's investment.

b.      Each Investor understands that no federal or state agency has made any finding or determination regarding the fairness of this Offering, or any recommendation or endorsement of this Offering.

 

c.      FOR PARTNERSHIPS, CORPORATIONS, TRUSTS, OR OTHER ENTITIES ONLY:  If the Investor is a partnership, corporation, trust, or other entity, (i),  the Investor represents and warrants that it was not organized or reorganized for the specific purpose of acquiring the Shares, (ii) the Investor has the full power and authority to execute this Agreement on behalf of such entity and to make the representations and warranties made herein on its behalf, and (iii) this investment in the Company has been affirmatively authorized, if required, by the governing board of such entity and is not prohibited by the governing documents of the entity.

 

 

  

3

  

 

d.      The address shown under the Investor's signature at the end of this Agreement is the Investor's principal residence if he or she is an individual, or its principal business address if a corporation or other entity.

5.           Except as otherwise specifically provided for hereunder, no party shall be deemed to have waived any of his, her, or its rights hereunder or under any other agreement, instrument, or papers signed by any of them with respect to the subject matter hereof unless such waiver is in writing and signed by the party waiving said right.  Except as otherwise specifically provided for hereunder, no delay or omission by any party in exercising any right with respect to the subject matter hereof shall operate as a waiver of such right or of any such other right.  A waiver on any one occasion with respect to the subject matter hereof shall not be construed as a bar to, or waiver of, any right or remedy on any future occasion.  All rights and remedies with respect to the subject matter hereof, whether evidenced hereby or by any other agreement, instrument, or paper, will be cumulative, and may be exercised separately or concurrently.

6.           This Agreement, together with any instruments executed simultaneously herewith, constitutes the entire agreement between the parties.

7.           This Agreement may not be changed, modified, extended, terminated, or discharged orally, but only by an agreement in writing, which is signed by the Company and the Investor.

8.           The parties agree to execute any and all such other and further instruments and documents, and to take any and all such further actions reasonably required to effectuate this Agreement and the intent and purposes hereof.

9.           If any provision or any portion of any provision of this Agreement or the application of any such provision or any portion thereof to any person or circumstance, shall be held invalid or unenforceable, the remaining portion of such provision and the remaining portion of such provision as is held invalid or unenforceable to persons or circumstances other than those as to which it is held invalid or unenforceable, shall not be affected thereby.

10.           This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware and the Investor hereby consents to the jurisdiction of the courts of the State of Delaware.

[Remainder of page intentionally left blank.]

 

 

  

4

  

 

ALL SUBSCRIBERS MUST COMPLETE A COPY OF THIS PAGE

_____________       _____________

(Print Name of Subscriber)

IN WITNESS WHEREOF, the Investor has executed this Agreement on this ____ day of ________, 2011.

	
Number of Shares:

	
Purchase Price Per Share: $1.50

	
Aggregate Common Stock Subscription Amount: $

Please indicate the form of ownership that you desire your Shares to be registered in.

	  	
1.

	
|__|

	
Individual

	  	  	  	  
	  	
2.

	
|__|

	
Joint Tenants with Right of Survivorship

	  	  	  	  
	  	
3.

	
|__|

	
Community Property

	  	  	  	  
	  	
4.

	
|__|

	
Tenants in Common

	  	  	  	  
	  	
5.

	
|__|

	
Corporation/Partnership

	  	  	  	  
	  	
6.

	
|__|

	
IRA of________________

	  	  	  	  
	  	
7.

	
|__|

	
Trust, Date Opened ___________

	  	  	  	  
	  	
8.

	
|__|

	
As A Custodian For________________ Under the Uniform Transfer to

	  	  	  	
Minors Act of the State of ___________

	  	  	  	  
	  	
9.

	
|__|

	
Married with Separate Property

	  	  	  	  
	  	
10.

	
|__|

	
Keogh  Plan ____________

[Remainder of page intentionally left blank.]

 

 

  

5

  

 

EXECUTION BY SUBSCRIBER WHO IS A NATURAL PERSON

	  
	
Exact Name in Which Title is to be Held

 

	  
	
(Signature)

 

	  
	
Name (Please Print)

 

	  
	
Title of Person Executing Agreement

 

	  
	
Address:  Number and Street

 

	  
	
City, State, Zip Code

 

	  
	
Social Security Number

 

Accepted this ___ day of _______, 2011, on behalf of Propanc Health Group Corporation

 

By: _____________________________

Name:

Title:

 

 

  

6

  

 

EXECUTION BY SUBSCRIBER WHICH IS A CORPORATION, PARTNER, TRUST, ETC.

	  
	
Exact Name in Which Title is to be Held

 

	  
	
(Signature)

 

	  
	
Name (Please Print)

 

	  
	
Title of Person Executing Agreement

 

	  
	
Address:  Number and Street

 

	  
	
City, State, Zip Code

 

	  
	
Tax Identification Number

 

Accepted this ___ day of _______, 2011 on behalf of Propanc Health Group Corporation

By: ________________________

      Name:

      Title:

 

 

  

7

  

 

	
  

	 

CONFIDENTIAL PROSPECTIVE PURCHASER QUESTIONNAIRE

THIS QUESTIONNAIRE IS TO BE COMPLETED BY EACH INVESTOR WHO DESIRES TO PURCHASE COMMON STOCK OF PROPANC HEALTH GROUP CORPORATION (THE” COMPANY”).  THIS MATERIAL DOES NOT CONSTITUTE AN OFFER TO SELL NOR IS IT A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES. THE TERMS OF THE OFFERING WILL BE MADE SOLELY PURSUANT TO SUBSCRIPTION AGREEMENT AND REGISTRATION STATEMENT PROVIDED HEREWITH WHICH CONTAINS MATERIAL INFORMATION TO BE REVIEWED IN CONNECTION WITH ANY INVESTMENT DECISION.

Please sign in the indicated space below and indicate the amount of your investment and put your initials after the amount.

Please check whether one or more of the following definitions of "Accredited Investor," if any, applies to you.

If you are not an Accredited Investor,  please leave all other  spaces blank and note under (h) that you are not an Accredited Investor.

	
         (a)

	
A Bank as defined in Section 3(a)(2) of the Securities Act of 1933, as amended (the "1933 Act"), or any savings and loan association or other institution as defined in Section 3(a)(5)(A) of the 1933 Act whether acting in its individual or fiduciary capacity; any broker or dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"); an insurance company as defined in Section 2(13) of the 1933 Act; an investment company registered under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of that act; a Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958; any plan established and maintained by a state, or its political subdivisions, or any agency or instrumentality of a state or its political subdivisions for the benefit of its employees, if such plan has total assets in excess of $5,000,000; any employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974, if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such act, which is either a bank, savings and loan association, insurance company, or registered investment advisor, or if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made solely by persons that are Accredited Investors.

 

	
        (b)

	
A Private Business Development Company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940.

 

	
        (c)

	
An organization described in Section 501(c)(3) of the Internal Revenue Code or corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000.

	
        (d)

	
A natural person whose individual net worth, or joint net worth with that person's spouse, at the time of purchase, exceeds $1,000,000.  In calculating net worth (or joint net worth with spouse), I have excluded the value my (or our) primary residence

	
        (e)

	
A natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with that person's spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year.

 

 

  

8

  

 

	
        (f)

	
Any trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the common stock, whose purchase is directed by a sophisticated person as described in Rule 506(b)(2)(ii) of Regulation D.

	
        (g)

	
Any entity in which all of the equity owners are Accredited Investors.

 

	
        (h)

	
I AM NOT AN ACCREDITED INVESTOR

 

	  	
$

	  	  	  
	
Investor’s Signature

	  	
Amount of Investment

	  	
Initials

	  	  	  	  	  
	  	  	  	  	  
	
(Please insert name in which Securities will be held; if held by a corporation, please sign below)

	  	  	  	  	  
	
Corporate Purchaser

	  	  	  	  
	
 

	

By:  

	  	  	  
	  	  	
Name/Title

	  	  

9ptx_ex101.htm

EXHIBIT 10.1

 

CONSULTING AGREEMENT

 

	
THIS CONSULTING AGREEMENT (this “Agreement”) is made on August __, 2011 (the “Effective Date”), between Pernix Therapeutics Holdings, Inc. (“Pernix”), located at 10003 Woodloch Forest Drive, The Woodlands, Texas 77380, and Jan Loeb (“Consultant”), having a place of business at c/o Leap Tide Capital Management, LLC, 10451 Mill Run Circle, Suite 400, Owings Mills, MD 21117.

 

Pernix has retained Consultant, on a non-exclusive basis, to perform certain Services (as defined below) in accordance with the terms herein.   The parties hereby agree as follows:

	 	
5.

	Confidentiality: Consultant shall not disclose, during the term of this Agreement and for five (5) consecutive years thereafter, the Confidential Information (defined below) of Pernix to a third party, except to the extent required to perform the Services hereunder and provided Consultant has entered into a confidentiality agreement with such third party with substantially the same terms as set forth in this Section 5.  “Confidential Information” shall mean any non-public technical, business, product and financial information, including, without limitation, financial data, marketing strategies, patent disclosures, patent applications, structures, models, techniques, processes, compositions, compounds, formulas, inventions, schematics, and apparatus of Pernix.  If Consultant is required by law or court to disclose the Confidential Information of Pernix, Consultant shall first provide immediate written notice to Pernix to enable Pernix at Pernix’s sole cost to obtain a protective order. Consultant shall not use the Confidential Information except as needed to perform the Services.  This Section 5 shall survive the termination of this Agreement.
	1.	Services: Consultant will timely perform the “Services” and only the “Services” described in the statement of work (“SOW”), substantially in the form attached hereto.	 	 
	 	 	 
	 	 	 	 
	2.	Compliance with Laws: Consultant shall perform the Services in accordance with applicable federal,state and local laws and regulations.	 	 
	 	 	 
	 	 	 	 
	3.	Relationship of Parties: The relationship of Consultant to Pernix is that of an independent contractor and not an employee, agent or partner of Pernix.  Nothing herein shall be construed ascreating any other relationship.	 	 
	 	 	 
	 	 	 	 
	 	 	 	6.	Compensation and Payment Terms:  Pernix shall pay Consultant the fees specified in the SOW.  Pernix will promptly reimburse Consultant for reasonable and customary expenses actually incurred by Consultant in connection with Consultant’s performance of the Services, in accordancewith the SOW; provided, however, that Consultant shall obtain the prior written approval of Pernix for any expenditure or group of related expenditures exceeding $2,000.  Upon completion of the  Services herein, Consultant shall invoice Pernix’s Accounts Payable Department and Pernix shall pay such invoice within forty-five (45) days after Pernix’s receipt thereof.
	4.	Consultant’s Agents:  Consultant shall select and have full and complete control over, and responsibility for, all actions of Consultant’s employees or other agents.  None of Consultant’sagents shall be, or shall be deemed to be, the agents of Pernix for any purpose whatsoever by virtue of this Agreement or otherwise. Consultant accepts liability for the payment of all taxes and/or contributions for unemployment insurance, pensions, annuities or social security payments that are measured by the wages, salaries or other remuneration paid to Consultant or Consultant’s agents, and Consultant shall reimburse and indemnify Pernix for any such taxes or contributions or penalties that Pernix may be compelled to pay.  This Section 4 shall survive the termination of this Agreement.	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

  

1

  

 

	7.	Acceleration of Vesting.  All options to purchase shares of Pernix’s common stock held by Consultant as of the Effective Date and not yet exercisable shall become exercisable over a twelve month period, with one-fourth of such outstanding options becoming exercisable on the 1st day of each fiscal quarter beginning October 1, 2011, and the option exercise price shall be payable at Consultant’s option through a “cashless” exercise arrangement. Notwithstanding the foregoing, any cashless exercise shall be made in accordance with Pernix’s then-current procedures and  policies for cashless exercise.  All shares of restricted stock of Pernix held by Consultant as of theEffective Date shall vest over a twelve month period, with one-fourth of the number of such shares free of any restriction and fully vested on the 1st day of each fiscal quarter beginning October 1, 2011. All other benefits or interests of Consultant in any of Pernix’s long term incentive plans or arrangements which are subject to vesting shall be vested in accordance with the schedule described above.	 	 	
If to Pernix:

	 	 	 	 
	 	 	 	Pernix Therapeutics Holdings, Inc.
	 	 	 	
10003 Woodloch Forest Drive

	 	 	 	
The Woodlands, Texas 77380Attn: Tracy Clifford

	 	 	 	
Tel: 843-720-1501

	 	 	 	
Fax:  843-723-0479

	 	 	 	 
	 	 	 	If to Consultant:
	 	 	 	 
	 	 	 	
Jan Loeb

	 	 	 	
c/o Leap Tide Capital Management, LLC

	 	 	 	 	
10451 Mill Run Circle, Suite 400

	8.	Materials and Work Product: All materials, documents and information of any kind supplied to  for Consultant by Pernix in connection with this Agreement shall remain the sole and exclusive property of Pernix, and upon termination of this Agreement, Consultant shall promptly return all such materials to Pernix.  Pernix shall be the exclusive owner of any and all reports, documents andmaterials created or produced by Consultant in performing the Services hereunder (the “Work Product”).  All Work Product that is copyrightable subject matter shall be considered “work made hire” within the meaning of the United States copyright laws and Pernix shall be sole owner thereof.	 	 	
Owings Mills, MD 21117

	 	 	 	
Ph: 410-654-3315

	 	 	 	
Fax: 410-654-3316

	 	 	 	
Email: jloeb@leaptidecapital.com

	 	 	 	 
	 	 	11.	Attorneys Fees.  Pernix shall pay Consultant’s attorneys’ fees in connection with the negotiation of this Agreement, such attorneys’ fees not to exceed $3,000.
	 	 	 
	 	 	 	 	 
	9.	Term and Termination: This Agreement shall commence on the Effective Date and shall continue for a period of four (4) years, unless terminated earlier as set forth below. Either party may terminate this Agreement upon 10 days’ prior written notice to the other party in the event the  other party breaches this Agreement and fails to cure such breach within such ten-day period.	 	12.	Governing Law: The laws of the State of Louisiana, without giving effect to its conflict and choice of law principles, shall govern all matters arising out of or relating to this Agreement.
	 	 	 
	 	 	 	 
	 	 	13.	Assignment:  Consultant shall not assign this Agreement or the Services to be performed hereunder to any other entity or person without the prior written consent of Pernix.
	 	 	 	 
	10.	Notice:  Any notice sent pursuant to this Agreement shall be in writing and shall be deemed effective upon receipt if sent (i) by courier, (ii) by prepaid registered or certified mail, (iii) by expedited delivery service, or  (iv) by facsimile transmission, receipt confirmed, addressed to the  parties at their respective addresses below, or such other address as either party may designate bywritten notice in accordance with this Section 10:	 	 	 
	 	 	14.	Complete Agreement; Conflicting Terms: This Agreement constitutes the entire agreement  in the parties hereto with respect to the subject matter hereof, and there are no other agreements orbetween  understandings, written or oral, between the parties relating to the subject matter of thisAgreement.  Any modification to or waiver of this Agreement shall not be effective unless executed writing by both parties.  If there is a conflict in the terms of this Agreement and the SOW issued pursuant to this Agreement, the terms of this Agreement shall control.  Pernix’s failure to object to conflicting terms in the SOW shall not be deemed to constitute Pernix’s acceptance of such conflicting terms.
	 	 	 
	 	 	 
	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

 

  

2

  

 

The parties have executed this Consulting Agreement as of the Effective Date.

 

	Pernix Therapeutics Holdings, Inc.	 
	 	 	 
	By:	/s/ Cooper C. Collins   	 
	Name:	Cooper C. Collins	 
	Title:	President and CEO	 
	 	 	 
	 	 	 
	 	Jan Loeb	 
	 	 	 
	By:	/s/ Jan Loeb	 

 

  

3

  

Exhibit “A”

to

Consulting Agreement

between Pernix Therapeutics, LLC and Jan Loeb

Consultant will timely and satisfactorily provide Pernix with the following services (the “Services”), for the fees set forth below:

	
1.  

	
Services.

Provide consulting advice up to five hours per calendar month to Pernix,  upon request of Pernix’s Chairman of the Board or Chief Executive Officer, relating to accounting or audit services, capital markets, compensation issues or corporate or business related matters.  Consultant shall, upon reasonable request of Pernix, prepare such memos, summaries or updates relating to the Services.  Consultant shall also make himself reasonably available to attend meetings of the board or directors or management, provided Consultant receives reasonable advance notice of such meetings.

	
2.  

	
Compensation.

Pernix shall pay Consultant on a monthly basis, fixed payments in an amount totaling an annual amount of $54,000 for the Services that Consultant timely and satisfactorily renders to or on behalf of Pernix.

	
3.  

	
Right of First Refusal.

	
(a)  

	
Grant.  During the term of this Agreement, Consultant hereby unconditionally and irrevocably grants to Pernix a right of first refusal to purchase from Consultant all or any portion of any Capital Stock that Consultant may propose to sell or offer to sell at a price equal to the average of the price per share as of the close of business on the two (2) business days immediately preceding such sale and on the same terms and conditions as those offered by Consultant, provided, however that Pernix shall not have a right of first refusal: (i) with respect to any charitable donations by Consultant of any Capital Stock; or (ii) with respect to any gifts of Capital Stock to family members.

	
(b)  

	
Notice.  Consultant must deliver written notice to Pernix not later than two (2) days prior to the consummation of such proposed transfer.  Such notice shall contain the material terms and conditions (including price and form of consideration) of the proposed transfer and the identity of the prospective transferee.  Pernix shall notify Consultant of its intention to purchase the Capital Stock within two (2) days from the receipt of Consultant’s notice and the closing of such transfer must occur within three (3) business days thereafter.

	
(c)  

	
Transfer Void.  Any proposed transfer not made in compliance with the requirements of this Agreement shall be null and void ab initio, shall not be recorded on the books of Pernix or its transfer agent and shall not be recognized by Pernix.

 

  

4

  

 

This Exhibit “A” is executed by the authorized agents of the parties below, as of the last date below, and is subject to the terms, covenants and conditions of, and is incorporated into, that certain Consulting Agreement entered into between the parties, dated August __, 2011.

 

	Pernix Therapeutics Holdings, Inc.	 	 	Jan Loeb	 
	 	 	 	 	 	 
	
By:

	  	  	
By:

	  	 
	  	  	  	  	  	 
	
Date:

	  	  	
Date:

	  	 

 

 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00196-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00196-of-00352.parquet"}]]